Biotech SF

San Francisco Bay Area biotech stories.

Showing posts with label AMRI. Show all posts
Showing posts with label AMRI. Show all posts

Tuesday, January 4, 2011

Genentech licenses NY biotech's potential antibacterial compounds

Posted by Unknown at 1:05 PM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: AMRI, Genentech
Older Posts Home
Subscribe to: Posts (Atom)

TOP STORIES

  • Patients' tales, biotech legends add weight to BayBio awards
    Genentech co-founder Herb Boyer. When two or more biotechs are gathered, you hear the usual phrases, including the old standby, “We'...
  • BNBuilders see project growth in health care, colleges
    BNBuilders' David Becker (left) and Sean Truesdale. David Becker and Sean Truesdale, principals at BNBuilders Inc.'s Redwood Cit...
  • UCSF partners schizophrenia treatments
    Bob Bennett and Rachel Loewy. Innovative treatment for schizophrenia by the Family Service Agency and researchers at UC San Francisco sh...
  • BioMarin shares rise on data from late-stage rare disease trial
    BioMarin CEO Jean-Jacques Bienaime. BioMarin Pharmaceutical Inc. will seek regulatory approval early next year of a drug to treat a crip...
  • Stanford team wins $20K for algorithm aimed at Lou Gehrig's disease drug trials
    Lester Mackey. A team from Stanford University won $20,000 for its work with algorithms that could reduce the number of Lou Gehrig’s Dis...

Some of my favorite stories.

• "The fight of his life" (2007)
Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)
Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)
Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)
Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.
All he needs now is $20 million.

Subscribe To

Posts
Atom
Posts
All Comments
Atom
All Comments

Blog Archive

  • ▼  2012 (486)
    • ▼  November (18)
      • Stanford team wins $20K for algorithm aimed at Lou...
      • Pearl Therapeutics grabs $65M in VC funding, moves...
      • Nation's HIV research general Tony Fauci: Cure in ...
      • Stanford self-healing skin could someday shield sm...
      • New wave of local companies tackles Lou Gehrig's d...
      • Buck Institute, partner spawn startup
      • Cerus to pursue U.S. approval of plasma safety system
      • Latest Genentech breast cancer drug, T-DM1, faces ...
      • Pharmacyclics stock sags on disappointing clinical...
      • Nile Therapeutics CEO takes 99.6% cut in pay -- bu...
      • Pathworks Diagnostics names Lee McCracken as CEO
      • BioMarin shares rise on data from late-stage rare ...
      • UCSF partners schizophrenia treatments
      • BNBuilders see project growth in health care, coll...
      • Patients' tales, biotech legends add weight to Bay...
      • Art and Drue Gensler make $5 million gift to the B...
      • Pfizer, Bristol-Myers Squibb to fund study of Port...
      • Advanced Cell Diagnostics lines up $12M Series B r...
    • ►  October (25)
    • ►  September (56)
    • ►  August (56)
    • ►  July (64)
    • ►  June (26)
    • ►  May (40)
    • ►  April (39)
    • ►  March (31)
    • ►  February (74)
    • ►  January (57)
  • ►  2011 (772)
    • ►  December (54)
    • ►  November (40)
    • ►  October (65)
    • ►  September (74)
    • ►  August (48)
    • ►  July (44)
    • ►  June (60)
    • ►  May (70)
    • ►  April (80)
    • ►  March (81)
    • ►  February (77)
    • ►  January (79)
  • ►  2010 (59)
    • ►  December (42)
    • ►  November (17)

Search This Blog

TWITTER UPDATES

Dates to Watch

Sept. 5 - PDUFA date for Salix Pharmaceuticals' crofelemer (developed by San Francisco's Napo Pharmaceuticals) for diarrhea in HIV/AIDS patients on antiretroviral therapy.
Oct. 19 - PDUFA date for Impax Pharmaceutical's IPX-066 in Parkinson's
Oct. 23 - PDUFA date for Hyperion Therapeutics' Ravicti in urea cycle disorders.

Calendar

  • "Ushering in the New Medical Device Excise Tax: Will You Be Ready?" 8 a.m. Wednesday, Sept. 5, Abbott Vascular, 3200 Lakeside Drive, Santa Clara. Cost: $20 BayBio members, $40 non-members (through Sept. 3) and $40 members and $75 non-members (after Sept. 3)
Unknown
View my complete profile

My contact information

Ron Leuty
San Francisco Business Times
275 Battery St.,
Suite 940
San Francisco,
CA 94111
415-288-4939 - direct
415-722-2678 - cell
rleuty@
bizjournals.com
http://www.bizjournals.com/sanfrancisco

Follow me on Twitter — rleuty_biotech
— or Facebook or LinkedIn.

For biotech stories from all of ACBJ's 40 business journals — from Boston to Seattle — go to Biotech Day.

Followers

Total Pageviews
Simple theme. Powered by Blogger.